Apellis Pharmaceuticals announced that its marketing application for pegcetacoplan, which is under priority review status, has been accepted by the FDA, with an action date set for May 14. Pegcetacoplan was developed to treat the rare blood disorder paroxysmal nocturnal hemoglobinuria.
FDA accepts application filed by Apellis for PNH drug
Sign up for Specialty Pharmacy SmartBrief
News affecting the specialty pharmacy industry
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.